GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Fujiwara, Satoe ^a   Terai, Yoshito ^a   Kawaguchi, Hiroshi ^a   Takai, Masaaki ^a   Yoo, Saha ^a   Tanaka, Yoshimichi ^a   Tanaka, Tomohito ^a   Tsunetoh, Satoshi ^a   Sasaki, Hiroshi ^a   Kanemura, Masanori ^a   Tanabe, Akiko ^a   Yamashita, Yoshiki ^a   Ohmichi, Masahide ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

7 transmembrane estrogen receptor; Akt; EGFR; ER ; Clear cell carcinomas; G protein coupled receptor 30; GPR30; Prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OMENTECTOMY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RETROPERITONEAL LYMPHADENECTOMY; SIGNAL TRANSDUCTION; SURVIVAL RATE; WESTERN BLOTTING;

EID: 84869125910     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-35     Document Type: Article

References (42)

1. Cancer statistics, 2010. Jemal A, Siegel R, Xu J, Ward E, CA Cancer J Clin 2010 60 277 300 10.3322/caac.20073 20610543
2. Estrogen stimulation of ovarian surface epithelial cell proliferation. Bai W, Oliveros-Saunders B, Wang Q, Acevedo-Duncan ME, Nicosia SV, In Vitro Cell Dev Biol Anim 2000 36 657 666 10.1290/1071-2690(2000)036<0657:ESOOSE>2.0. CO;2 11229598 (Pubitemid 32164666)
3. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ, JAMA 2001 285 1460 1465 10.1001/jama.285.11.1460 11255422 (Pubitemid 32221894)
4. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish woman. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR, J Natl Cancer Inst 2002 94 497 504 10.1093/jnci/94.7.497 11929950 (Pubitemid 34411288)
5. Menopausal hormone replacement therapy and risk of ovarian cancer. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C, JAMA 2002 288 334 341 10.1001/jama.288.3.334 12117398 (Pubitemid 34761612)
6. The multifaceted mechanisms of estradiol and estrogen receptor signaling. Hall JM, Couse JF, Korach KS, J Biol Chem 2001 276 36869 36872 10.1074/jbc.R100029200 11459850
7. Chemical interference with genomic and nongenomic actions of steroids in fishes: role of receptor binding. Thomas P, Mar Environ Res 2000 50 127 134 10.1016/S0141-1136(00)00114-8 11460678
8. Expression of oestrogen receptor alpha and beta in cultured human ovarian surface epithelial cells. Hiller SG, Anderson RA, Williams AR, Tetsuka M, Mol Hum Reprod 1998 4 811 815 10.1093/molehr/4.8.811 9733440 (Pubitemid 28392026)
9. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffargue F, Rochefort H, Maudelonde T, Cancer Res 1998 58 5367 5373 9850067 (Pubitemid 28551118)
10. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. Brandenberger AW, Tee MK, Jaffe RB, J Clin Endocrinol Metab 1998 83 1025 1028 10.1210/jc.83.3.1025 9506768 (Pubitemid 28496985)
11. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. Kuiper GG, Gustafsson JA, FEBS Lett 1997 410 87 90 10.1016/S0014-5793(97)00413-4 9247129 (Pubitemid 27283390)
12. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Monoz A, Mor G, Obstet Gynecol 2000 96 417 421 10.1016/S0029-7844(00)00917-0 10960636
13. Endocrine factors in common epithelial ovarian cancer. Rao BR, Slotman BJ, Endocr Rev 1991 12 14 26 10.1210/edrv-12-1-14 1851084
14. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Hatch KD, Beecham JB, Blessing JA, Creasman WT, Cancer 1991 68 269 271 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O 2070324
15. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Perez-Gracia JL, Carrasco EM, Gynecol Oncol 2002 84 201 209 10.1006/gyno.2001.6489 11812075 (Pubitemid 34139799)
16. The G-protein-coupled estrogen receptor GPER in health and disease. Prossnitz ER, Barton M, Nat Rev Endocrinol 2011 7 715 726 10.1038/nrendo.2011. 122 21844907
17. GPR30: a novel indicator of poor survival for endometrial carcinoma. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, Prossnitz ER, Am J Obstet Gynecol 2007 196 4 386 e381 386 e389 discussion 386 e389-11
18. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Andò S, Maggiolini M, Cancer Res 2007 67 1859 1866 10.1158/0008-5472.CAN-06-2909 17308128 (Pubitemid 46383413)
19. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, Andò S, J Biol Chem 2004 279 27008 27016 10.1074/jbc.M403588200 15090535 (Pubitemid 38812536)
20. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and ocurrs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr, Mol Endocrinol 2000 14 1649 1660 10.1210/me.14.10.1649 11043579
21. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. He YY, Cai B, Yang YX, Liu XL, Wan XP, Cancer Sci 2009 100 1051 1061 10.1111/j.1349-7006.2009.01148.x 19432902
22. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E, Clin Cancer Res 2006 12 6359 6366 10.1158/1078-0432.CCR-06-0860 17085646 (Pubitemid 44799705)
23. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D, EMBO J 2009 28 523 532 10.1038/emboj.2008.304 19153601
24. 17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30. Kleuser B, Malek D, Gust R, Pertz HH, Potteck H, Mol Pharmacol 2008 74 1533 1543 10.1124/mol.108.046854 18768737
25. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. Filardo EJ, J Steroid Biochem Mol Biol 2002 80 231 238 10.1016/S0960-0760(01)00190-X 11897506 (Pubitemid 34233742)
26. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER, Cristofanilli M, Breast Cancer Res Treat 2010 123 51 58 10.1007/s10549-009-0631- 7 19902352
27. Virtual and biomolecular screening converge on a selective agonist for GPR30. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER, Nat Chem Biol 2006 2 207 212 10.1038/nchembio775 16520733
28. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Thomas P, Pang Y, Filardo EJ, Dong J, Endocrinology 2005 146 624 632 15539556 (Pubitemid 40129818)
29. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S, Maggiolini M, Mol Endocrinol 2006 20 631 646 16239258 (Pubitemid 43291214)
30. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, et al. Am J Obstet Gynecol 1991 164 669 674 1992720
31. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA, Clin Cancer Res 2005 11 8637 8643 10.1158/1078-0432.CCR-05-1436 16361548 (Pubitemid 43005911)
32. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Vivanco I, Sawyers CL, Nat Rev Cancer 2002 2 489 501 10.1038/nrc839 12094235 (Pubitemid 37328931)
33. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Tanaka Y, Terai Y, Tanabe A, Sasaki H, Sekijima T, Fujiwara S, Yamashita Y, Kanemura M, Ueda M, Sugita M, Franklin WA, Ohmichi M, Cancer Biol Ther 2011 11 50 57 10.4161/cbt.11.1.13877 21057220
34. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Tsunetoh S, Terai Y, Sasaki H, Tanabe A, Tanaka Y, Sekijima T, Fujioka S, Kawaguchi H, Kanemura M, Yamashita Y, Ohmichi M, Cancer Biol Ther 2010 10 1137 1146 10.4161/cbt.10.11.13443 20935474
35. GPR30 predicts poor survival for ovarian cancer. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER, Gynecol Oncol 2009 114 465 471 10.1016/j.ygyno.2009.05.015 19501895
36. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM, Cancer Res 2001 61 6768 6776 11559549 (Pubitemid 32896499)
37. Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. Nash JD, Ozols RF, Smyth JF, Hamilton TC, Obstet Gynecol 1989 73 1009 1016 10.1097/00006250-198906000-00021 2542854 (Pubitemid 19143840)
38. G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR, Dolce V, Abonante S, Pezzi V, Maggiolini M, Environ Health Perspect 2008 116 1648 1655 10.1289/ehp.11297 19079715
39. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS, Pathol Int 2008 58 749 756 10.1111/j.1440-1827.2008.02306.x 19067848
40. The G protein-coupled estrogen receptor 1 (GPER/GPR30) dose not predict survival in patients with ovarian cancer. Kolkova Z, Casslen V, Henic E, Ahmadi S, Ehinger A, Jirstrom K, Casslen B, J Ovarian Res 2012 5 9 10.1186/1757-2215-5- 9 22424333
41. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Itamochi H, Yoshida T, Walker CL, Bartholomeusz C, Aoki D, Ishihara H, Suzuki N, Kigawa J, Terakawa N, Ueno NT, Gynecol Oncol 2011 122 641 647 10.1016/j.ygyno.2011.05.003 21652059
42. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. Gilks CB, J Oncol 2010 Article ID 740968